Definium Therapeutics, Inc. Common Shares DFTX
i
Market datapartial · fetched 2026-11-11T12:27:52.411Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T12:16:15.329161869Z
FundamentalsAlpha Vantage · unavailable
Definium Therapeutics, Inc. Common Shares options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 30.71 | 97.1% | 12.8% | |||
| 25Δ | 31.55 | 95.6% | 11.0% | |||
| 30Δ | 32.25 | 97.6% | 9.7% | |||
| 35Δ | 36.90 | 92.2% | 10.1% | 32.88 | 102.4% | 8.9% |
| 40Δ | 36.27 | 95.2% | 9.1% | |||
| 45Δ | 35.63 | 99.1% | 8.1% | 34.32 | 86.1% | 5.6% |
| 50Δ | 34.99 | 103.4% | 7.3% | 34.97 | 99.8% | 5.6% |
| 55Δ | 34.31 | 90.0% | 5.4% | |||
| 60Δ | 33.62 | 89.7% | 4.4% | |||
| 65Δ | 32.88 | 101.6% | 4.2% | |||
| 70Δ | 37.70 | 92.9% | 2.5% | |||
| 75Δ | 30.53 | 139.8% | 3.8% | 39.32 | 109.7% | 2.3% |
| 80Δ | 28.96 | 155.6% | 3.2% | 39.77 | 98.4% | 1.6% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 30.71
- IV
- 97.1%
- B/E move
- 12.8%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 31.55
- IV
- 95.6%
- B/E move
- 11.0%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 32.25
- IV
- 97.6%
- B/E move
- 9.7%
35Δ
- Pseudo strike
- 36.90
- IV
- 92.2%
- B/E move
- 10.1%
- Pseudo strike
- 32.88
- IV
- 102.4%
- B/E move
- 8.9%
40Δ
- Pseudo strike
- 36.27
- IV
- 95.2%
- B/E move
- 9.1%
- Pseudo strike
- IV
- B/E move
45Δ
- Pseudo strike
- 35.63
- IV
- 99.1%
- B/E move
- 8.1%
- Pseudo strike
- 34.32
- IV
- 86.1%
- B/E move
- 5.6%
50Δ
- Pseudo strike
- 34.99
- IV
- 103.4%
- B/E move
- 7.3%
- Pseudo strike
- 34.97
- IV
- 99.8%
- B/E move
- 5.6%
55Δ
- Pseudo strike
- 34.31
- IV
- 90.0%
- B/E move
- 5.4%
- Pseudo strike
- IV
- B/E move
60Δ
- Pseudo strike
- 33.62
- IV
- 89.7%
- B/E move
- 4.4%
- Pseudo strike
- IV
- B/E move
65Δ
- Pseudo strike
- 32.88
- IV
- 101.6%
- B/E move
- 4.2%
- Pseudo strike
- IV
- B/E move
70Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 37.70
- IV
- 92.9%
- B/E move
- 2.5%
75Δ
- Pseudo strike
- 30.53
- IV
- 139.8%
- B/E move
- 3.8%
- Pseudo strike
- 39.32
- IV
- 109.7%
- B/E move
- 2.3%
80Δ
- Pseudo strike
- 28.96
- IV
- 155.6%
- B/E move
- 3.2%
- Pseudo strike
- 39.77
- IV
- 98.4%
- B/E move
- 1.6%
Options history
Table
| Date | IV (%) |
|---|---|
| 65.16% | |
| 64.28% | |
| 64.82% | |
| 63.27% | |
| 67.41% | |
| 65.18% | |
| 66.80% | |
| 67.22% | |
| 65.47% | |
| 69.49% |
Biotechnology
DMAC
DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company is headquartered in Minneapolis,…
More →DNA
Ginkgo Bioworks Holdings (DNA) is a pioneering force in synthetic biology, leveraging advanced genetic engineering to create customized bioengineered organisms suitable for a wide…
More →DNLI
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company is…
More →DNTH
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and…
More →DRTS
Alpha Tau Medical Ltd., a clinical-stage oncology therapies company, is engaged in the research, development, and commercialization of alpha-emitting radiation therapy (Alpha…
More →DRUG
Bright Minds Biosciences Inc. (DRUG) is a forward-thinking clinical-stage biotechnology firm specializing in the development of groundbreaking therapies for central nervous system…
More →